Department of Biostatistics, University of North Carolina, 3109 McGavran-Greenberg Hall, CB #7420, Chapel Hill, NC, 27599, USA.
Department of Data Science, Product Development, Genentech, Inc, South San Francisco, CA, USA.
BMC Med Res Methodol. 2024 Nov 1;24(1):264. doi: 10.1186/s12874-024-02383-3.
The use of historical external control data in clinical trials has grown in interest and needs when considering the design of future trials. Hybrid control designs can be more efficient to achieve the same power with fewer patients and limited resources. The literature is sparse on appropriate statistical methods which can account for the differences between historical external controls and the control patients in a study. In this article, we illustrate the analysis framework of a clinical trial if a hybrid control design was used after determining an RCT may not be feasible.
We utilize two previously completed RCTs in nonsquamous NSCLC and a nationwide electronic health record derived de-identified database as examples and compare 5 analysis methods on each trial, as well as a set of simulations to determine operating characteristics of such designs.
In single trial estimation, the Case Weighted Adaptive Power Prior provided estimated treatment hazard ratios consistent with the original trial's conclusions with narrower confidence intervals. The simulation studies showed that the Case Weighted Adaptive Power Prior achieved the highest power (and well controlled type-1 error) across all 5 methods with consistent study sample size.
By following the proposed hybrid control framework, one can design a hybrid control trial transparently and accounting for differences between control groups while controlling type-1 error and still achieving efficiency gains from the additional contribution from external controls.
在考虑未来试验的设计时,临床试验中使用历史外部对照数据的兴趣和需求不断增加。混合对照设计可以更有效地利用更少的患者和有限的资源来实现相同的效力。关于可以解释历史外部对照与研究中对照患者之间差异的适当统计方法,文献还很缺乏。本文通过确定 RCT 可能不可行后使用混合对照设计,说明了临床试验的分析框架。
我们利用两个先前完成的非鳞状 NSCLC 的 RCT 和一个全国性的电子健康记录衍生的去识别数据库作为例子,并对每个试验比较了 5 种分析方法,以及一系列模拟来确定这种设计的操作特征。
在单试验估计中,病例加权自适应功效先验法提供的治疗风险比与原始试验的结论一致,置信区间较窄。模拟研究表明,病例加权自适应功效先验法在所有 5 种方法中都实现了最高的功效(以及良好控制的Ⅰ型错误),具有一致的研究样本量。
通过遵循拟议的混合对照框架,可以透明地设计混合对照试验,并考虑对照的差异,同时控制Ⅰ型错误,并且仍然可以从外部对照的额外贡献中获得效率提高。